BREAKING: These S&P 500 Stocks Dive On Fed Shutdown Deal Investors.com will undergo scheduled maintenance from 10:00 PM ET to 2:00 AM ET and some features may be unavailable. We apologize for any inconvenience. Roche (RHHBY) presented what it called "unprecedented" test results for its multiple sclerosis treatment, putting pressure on key rival TG Therapeutics (TGTX). In morning trades on today's stock market, Roche stock rose more than 3% to 43.33, while TG shares tumbled more than 5% to 30.53. That put TG ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the first Phase III (FENhance 2) of two pivotal, similarly-designed Phase III studies (FENhance 1 and 2) in patients with relapsing multiple sclerosis (RMS) met its primary endpoint. Fenebrutinib, an investigational Bruton's tyrosine kinase (BTK) inhibitor, significantly reduced the annualized relapse rate (ARR) compared to teriflunomide over a period of at lea. ...